You are here: Industry Insights > Everest Medicines

News List

What is the Confidence of this Pharmaceutical Company To Target its Sales Peak of CNY 10 Billion? Xiaobin/PharmaSources
August 07, 2023
Recently, at Everest Medicines' investor exchange activities, the management led by CEO Luo Yongqing put forward the target of "realizing the marketing of four commercial products in a short time, with a sales peak of CNY 10 billion".
Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY Everest Medicines Limited
December 20, 2024
Everest Medicines announced NMPA acceptance of NDA for VELSIPITY(R) (etrasimod) to treat moderately to severely active UC.
Everest Medicines Announces the First Prescription of VELSIPITY® Issued in Macau, Officially Beginning to Benefit Asian Patients PharmaSources
December 12, 2024
Everest Medicines today announced that the first prescription of VELSIPITY® (etrasimod) has been issued on December 11th at Kiang Wu Hospital in Macau.
Everest Medicines Announces Acceptance of VELSIPITY New Drug Application in Hong Kong PharmaSources
December 03, 2024
Everest Medicines today announced that Department of Health of the Government of the Hong Kong Special Administrative Region, China, has accepted Everest’s New Drug Application (NDA).
Everest Medicines, Singapore's EDDC Enter Global Licensing Agreement for COVID Oral Antivirals contractpharma
January 17, 2022
Everest gains exclusive global rights to a series of 3CL protease inhibitors to treat COVID-19.
Everest Medicines Will Participate in a Clinical Trial with Gilead and MSD to Evaluate Trodelvy® in Combination with KEYTRUDA® (pembrolizumab) in First-Line Metastatic Non-Small Cell Lung Cancer prnasia
January 11, 2022
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), today announced it will participate in a study pursuant to a clinical trial collaboration between Gilead and MSD...
Everest Medicines Announces Taiwan, China,China FDA Has Accepted New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer prnasia
January 04, 2022
Everest Medicines Limited (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products in Asia...
Providence Therapeutics and Everest Medicines announces that PTX-COVID19-B, a mRNA Vaccine for COVID-19, has received approval for inclusion in WHO Solidarity Trial Vaccines (STV) Program prnewswire
December 21, 2021
Providence Therapeutics and Everest Medicines announced today that their COVID-19 vaccine, PTX-COVID19-B, has been recommended by an independent advisory group to be part of the Solidarity Trial Vaccines ("STV") clinical trial.
Everest Medicines Announces the Acceptance of a New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer in South Korea prnasia
December 15, 2021
Everest Medicines Limited (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products...
Everest Medicines and Providence Therapeutics Jointly Announce Vaccine Development Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant prnasia
December 01, 2021
Everest Medicines and Providence Therapeutics ("Providence") jointly announced today that the companies have started working on a new version of COVID-19 vaccine specifically targeting the new Omicron variant.

Previous page 1 2 3 Next page